Sohm(OTC) SHMN

SOHM, Inc. is a healthcare company focused on developing, manufacturing, marketing, and distributing generic and private label pharmaceutical products in the United States. The company offers a diverse range of products, including analgesics, antibiotics, and nutraceuticals, while also engaging in genome editing collaborations.

Products and Services

• Generic and private label pharmaceutical products
• Analgesics, antibiotics, and anti-inflammatory drugs
• Cosmeceuticals and nutraceuticals

Growth Outlook

• Recent quarterly revenue increased to $299,216, showing potential for growth
• Gross profit margin improved to 75.98% in Q4 2025
• Collaboration with Coastar Therapeutics may enhance product offerings

Financial Highlights

• Trailing twelve months (TTM) P/E ratio stands at 4.00, indicating potential value
• Recent quarterly net income of -$64,691 reflects ongoing challenges
• Current ratio of 1.08 suggests adequate short-term financial health

SOHM, Inc. operates in the medical and pharmaceutical industry, providing a variety of essential healthcare products. The company has shown resilience in its revenue generation, with a notable increase in gross profit margin, indicating effective cost management. The collaboration with Coastar Therapeutics could position SOHM, Inc. favorably in the evolving landscape of genome editing, potentially leading to innovative product developments. Despite facing challenges reflected in recent net income figures, the company's financial ratios suggest a foundation for future growth. Investors may find interest in the company's strategic direction and product diversification as it navigates the competitive pharmaceutical market.